Ryeo Gang Son
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ryeo Gang Son has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Seung Pil Pack
Department of Biotechnology and Bioinformatics, Korea University, Sejong 30019, Republic of Korea
4 shared publications - Mi-Ran Ki
Department of Biotechnology and Bioinformatics, Korea University, Sejong-Ro 2511, Sejong 30019, Republic of Korea
2 shared publications - Mohamed A. A. Abdelhamid
Department of Biotechnology and Bioinformatics, Korea University, Sejong-Ro 2511, Sejong 30019, Republic of Korea
2 shared publications - Amer Ali Abd El-Hafeez
Department of Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University School of Medicine, Stanford, CA 94304, USA
1 shared publication Anna Choi
Department of Biotechnology and Bioinformatics, Korea University, Sejong, 30019, Republic of Korea
1 shared publication- Gyudo Lee
Department of Biotechnology and Bioinformatics, Korea University, Sejong 30019, Republic of Korea
1 shared publication
Latest Publications
- 20 July 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 277 (Pt 2) , 134058
Biosilica-coated carbonic anhydrase displayed on Escherichia coli: A novel design approach for efficient and stable biocatalyst for CO2 sequestration
- 20 July 2024
- Published by Elsevier in International Journal of Biological Macromolecules
- Vol. 277 (Pt 2) , 134058
Biosilica-coated carbonic anhydrase displayed on Escherichia coli: A novel design approach for efficient and stable biocatalyst for CO2 sequestration
- Open Access
- 3 January 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 168
Tailored Functionalized Protein Nanocarriers for Cancer Therapy: Recent Developments and Prospects
Recently, the potential use of nanoparticles for the targeted delivery of therapeutic and diagnostic agents has garnered increased interest. Several nanoparticle drug delivery systems have been developed for cancer treatment. Typically, protein-based nanocarriers offer several advantages, including biodegradability and biocompatibility. Using genetic engineering or chemical conjugation approaches, well-known naturally occurring protein nanoparticles can be further prepared, engineered, and functionalized in their self-assembly to meet the demands of clinical production efficiency. Accordingly, promising protein nanoparticles have been developed with outstanding tumor-targeting capabilities, ultimately overcoming multidrug resistance issues, in vivo delivery barriers, and mimicking the tumor microenvironment. Bioinspired by natural nanoparticles, advanced computational techniques have been harnessed for the programmable design of highly homogenous protein nanoparticles, which could open new routes for the rational design of vaccines and drug formulations. The current review aims to present several significant advancements made in protein nanoparticle technology, and their use in cancer therapy. Additionally, tailored construction methods and therapeutic applications of engineered protein-based nanoparticles are discussed.
- 3 January 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (1) , 168
Open AccessTailored Functionalized Protein Nanocarriers for Cancer Therapy: Recent Developments and Prospects
Recently, the potential use of nanoparticles for the targeted delivery of therapeutic and diagnostic agents has garnered increased interest. Several nanoparticle drug delivery systems have been developed for cancer treatment. Typically, protein-based nanocarriers offer several advantages, including biodegradability and biocompatibility. Using genetic engineering or chemical conjugation approaches, well-known naturally occurring protein nanoparticles can be further prepared, engineered, and functionalized in their self-assembly to meet the demands of clinical production efficiency. Accordingly, promising protein nanoparticles have been developed with outstanding tumor-targeting capabilities, ultimately overcoming multidrug resistance issues, in vivo delivery barriers, and mimicking the tumor microenvironment. Bioinspired by natural nanoparticles, advanced computational techniques have been harnessed for the programmable design of highly homogenous protein nanoparticles, which could open new routes for the rational design of vaccines and drug formulations. The current review aims to present several significant advancements made in protein nanoparticle technology, and their use in cancer therapy. Additionally, tailored construction methods and therapeutic applications of engineered protein-based nanoparticles are discussed.
- Open Access
- 1 January 2021
- Published by XMLink in Immune Network
- Vol. 21 (3) , e24
Effect of Human or Mouse IL-7 on the Homeostasis of Porcine T Lymphocytes
Hong JH, et al. Immune Netw. 2021 Jun;21(3):e24. https://doi.org/10.4110/in.2021.21.e24
- 1 January 2021
- Published by XMLink in Immune Network
- Vol. 21 (3) , e24
Open AccessEffect of Human or Mouse IL-7 on the Homeostasis of Porcine T Lymphocytes
Hong JH, et al. Immune Netw. 2021 Jun;21(3):e24. https://doi.org/10.4110/in.2021.21.e24